Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1997 1
2007 3
2011 1
2012 1
2013 1
2014 2
2015 2
2017 1
2018 6
2019 5
2020 9
2021 8
2022 3
2023 5
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Reynolds JV, et al. Among authors: turkington rc. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. doi: 10.1016/S2468-1253(23)00243-1. Epub 2023 Sep 18. Lancet Gastroenterol Hepatol. 2023. PMID: 37734399 Free PMC article. Clinical Trial.
Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
Moore JL, Green M, Santaolalla A, Deere H, Evans RPT, Elshafie M, Lavery A, McManus DT, McGuigan A, Douglas R, Horne J, Walker R, Mir H, Terlizzo M, Kamarajah SK, Van Hemelrijck M, Maisey N, Sita-Lumsden A, Ngan S, Kelly M, Baker CR, Kumar S, Lagergren J, Allum WH, Gossage JA, Griffiths EA, Grabsch HI, Turkington RC, Underwood TJ, Smyth EC, Fitzgerald RC, Cunningham D, Davies AR; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study group, The Guy's and St Thomas' Oesophago-gastric Research Group, and The PROGRESS study group. Moore JL, et al. Among authors: turkington rc. J Clin Oncol. 2023 Oct 1;41(28):4522-4534. doi: 10.1200/JCO.23.00139. Epub 2023 Jul 27. J Clin Oncol. 2023. PMID: 37499209
The Multiple Roles of the IAP Super-family in cancer.
Kumar S, Fairmichael C, Longley DB, Turkington RC. Kumar S, et al. Among authors: turkington rc. Pharmacol Ther. 2020 Oct;214:107610. doi: 10.1016/j.pharmthera.2020.107610. Epub 2020 Jun 23. Pharmacol Ther. 2020. PMID: 32585232 Review.
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline.
Vikas P, Messersmith H, Compton C, Sholl L, Broaddus RR, Davis A, Estevez-Diz M, Garje R, Konstantinopoulos PA, Leiser A, Mills AM, Norquist B, Overman MJ, Sohal D, Turkington RC, Johnson T. Vikas P, et al. Among authors: turkington rc. J Clin Oncol. 2023 Apr 1;41(10):1943-1948. doi: 10.1200/JCO.22.02462. Epub 2023 Jan 5. J Clin Oncol. 2023. PMID: 36603179
46 results